Player FM ऐप के साथ ऑफ़लाइन जाएं!
Breakthrough in Melanoma, Rare Diseases, and Curative Therapies with Scott Schliebner
Manage episode 434915808 series 3593861
Summary
In this episode, Scott Schliebner discusses the unique challenges and complexities of rare disease trials. He highlights the difficulties in recruiting patients, the multidisciplinary nature of care, and the importance of collaboration among various stakeholders. The role of AI in rare disease trials is also explored, with a focus on its potential for patient recruitment and data analysis.
Scott shares success stories in the field and discusses the expanding use of gene therapy to target multiple genes. The conversation concludes with a discussion on the recent FDA approval of Iovance's Amtogvy as the first T-cell therapy for a solid tumor, Melanoma. In this conversation, Scott discusses the potential of cell therapy in targeting solid tumors, particularly melanoma. He highlights the importance of expanding the use of cell therapy to other tumor types and the potential for curative treatments. The conversation also delves into the challenges and questions surrounding pricing and ethics in the gene and cell therapy space. The impact of curative therapies on quality of life and healthcare costs is explored, along with the success of curative therapies in hepatitis C. The high bar of clinical development and regulatory standards is discussed, as well as the potential for cost-effective treatments. The conversation concludes with advice for young professionals and established clinical professionals in the field of drug development.
Takeaways
Cell therapy shows promise in targeting solid tumors, such as the breakthrough in melanoma treatment, and has the potential to provide curative treatments for various cancer types.
The pricing and ethical considerations surrounding gene and cell therapy raise important questions about accessibility and affordability.
Curative therapies have the potential to significantly improve quality of life and reduce healthcare costs by eliminating the need for long-term treatments.
The success of curative therapies in hepatitis C demonstrates the potential for similar breakthroughs in other disease areas.
Young professionals interested in a career in clinical drug development should seek opportunities to gain experience and consider starting in roles such as clinical research coordinators or clinical research associates.
Rare Givers is a nonprofit organization that supports caregivers in the rare disease space.
Chapters
00:21 - Collaborative Approach in Rare Disease Trials
3:32 - The Role of AI in Rare Disease Trials
6:11 - Success Stories in Rare Disease Trials
11:34 - Expanding Gene Therapy to Target Multiple Genes
16:56 - New News: FDA Approval of Iovance's Amtagvi, The Breakthrough of IOVANCE for Melanoma
19:27 - Targeting Solid Tumors with Cell Therapy, Expanding the Potential of Cell Therapy
20:23 - The Impact of Curative Therapies on Quality of Life and Healthcare Costs
21:11 - Challenges and Questions around Pricing and Ethics
22:37 - Cures for Hepatitis C
23:25 - The High Bar of Clinical Development and Regulatory Standards
24:05 - Pricing Considerations for Different Cancer Types, The Potential for Cost-Effective Treatments
27:45 - Advice for Young Professionals in Clinical Drug Development
31:49 - Advice for Established Clinical Professionals
33:21 - Scott's Hobbies and Interests
Learn about and DONATE to Rare Givers:
https://www.raregivers.global/
How to reach us:
Scott Schliebner
https://www.linkedin.com/in/scott-schliebner-1087789/
Dr. Chad Briscoe
https://www.linkedin.com/in/chadbriscoe/
Gregory Austin
https://www.linkedin.com/in/gregoryaustin1/
New News Link:
https://www.fiercepharma.com/pharma/fda-approves-iovances-amtagvi-first-cell-therapy-solid-tumor
Image Credits
Iovance, https://www.iovance.com/
FDA approved, https://www.tipranks.com/news/iovance-nasdaqiova-fda-approves-cell-therapy-stock-gains
Amtagvi, https://www.amtagvi.com/
29 एपिसोडस
Manage episode 434915808 series 3593861
Summary
In this episode, Scott Schliebner discusses the unique challenges and complexities of rare disease trials. He highlights the difficulties in recruiting patients, the multidisciplinary nature of care, and the importance of collaboration among various stakeholders. The role of AI in rare disease trials is also explored, with a focus on its potential for patient recruitment and data analysis.
Scott shares success stories in the field and discusses the expanding use of gene therapy to target multiple genes. The conversation concludes with a discussion on the recent FDA approval of Iovance's Amtogvy as the first T-cell therapy for a solid tumor, Melanoma. In this conversation, Scott discusses the potential of cell therapy in targeting solid tumors, particularly melanoma. He highlights the importance of expanding the use of cell therapy to other tumor types and the potential for curative treatments. The conversation also delves into the challenges and questions surrounding pricing and ethics in the gene and cell therapy space. The impact of curative therapies on quality of life and healthcare costs is explored, along with the success of curative therapies in hepatitis C. The high bar of clinical development and regulatory standards is discussed, as well as the potential for cost-effective treatments. The conversation concludes with advice for young professionals and established clinical professionals in the field of drug development.
Takeaways
Cell therapy shows promise in targeting solid tumors, such as the breakthrough in melanoma treatment, and has the potential to provide curative treatments for various cancer types.
The pricing and ethical considerations surrounding gene and cell therapy raise important questions about accessibility and affordability.
Curative therapies have the potential to significantly improve quality of life and reduce healthcare costs by eliminating the need for long-term treatments.
The success of curative therapies in hepatitis C demonstrates the potential for similar breakthroughs in other disease areas.
Young professionals interested in a career in clinical drug development should seek opportunities to gain experience and consider starting in roles such as clinical research coordinators or clinical research associates.
Rare Givers is a nonprofit organization that supports caregivers in the rare disease space.
Chapters
00:21 - Collaborative Approach in Rare Disease Trials
3:32 - The Role of AI in Rare Disease Trials
6:11 - Success Stories in Rare Disease Trials
11:34 - Expanding Gene Therapy to Target Multiple Genes
16:56 - New News: FDA Approval of Iovance's Amtagvi, The Breakthrough of IOVANCE for Melanoma
19:27 - Targeting Solid Tumors with Cell Therapy, Expanding the Potential of Cell Therapy
20:23 - The Impact of Curative Therapies on Quality of Life and Healthcare Costs
21:11 - Challenges and Questions around Pricing and Ethics
22:37 - Cures for Hepatitis C
23:25 - The High Bar of Clinical Development and Regulatory Standards
24:05 - Pricing Considerations for Different Cancer Types, The Potential for Cost-Effective Treatments
27:45 - Advice for Young Professionals in Clinical Drug Development
31:49 - Advice for Established Clinical Professionals
33:21 - Scott's Hobbies and Interests
Learn about and DONATE to Rare Givers:
https://www.raregivers.global/
How to reach us:
Scott Schliebner
https://www.linkedin.com/in/scott-schliebner-1087789/
Dr. Chad Briscoe
https://www.linkedin.com/in/chadbriscoe/
Gregory Austin
https://www.linkedin.com/in/gregoryaustin1/
New News Link:
https://www.fiercepharma.com/pharma/fda-approves-iovances-amtagvi-first-cell-therapy-solid-tumor
Image Credits
Iovance, https://www.iovance.com/
FDA approved, https://www.tipranks.com/news/iovance-nasdaqiova-fda-approves-cell-therapy-stock-gains
Amtagvi, https://www.amtagvi.com/
29 एपिसोडस
सभी एपिसोड
×1 The Future of Pharmacometrics with Dr. Nathan Teuscher 33:15
1 Insights from AAPS PharmSci 360 Live with Dr. Mark Arnold 29:49
1 Digital Twins: The Future of Drug Discovery with Dr. Tomáš Helikar 37:38
1 Transforming Immunology: The Promise of Digital Twins with Dr. Tomáš Helikar 32:28
1 How AI is Transforming Drug Development: Reflections from AAPS - PharmSci 360 with Dr. Mark Arnold 36:11
1 Biotech Funding Trends and the Rise of Digital Twinning with CEO Scott Ogle 29:40
1 Technology Meets Purpose: Transforming Clinical Trials at TruLab with CEO Scott Ogle 33:36
1 Mentoring in Pharmaceutical Science with Dr. Jim Shen 35:07
1 Great Advances in Cancer Research with Dr. Jim Shen 37:19
1 The Future of Hybrid Healthcare: Insights from Zealic CEO Chuck Piccirillo 39:31
1 Genetic Diagnostics & Student CEOs with Dr. Jonathon Hill 33:17
1 How AI is Helping Diagnose Disease with Chuck Piccirillo 38:04
1 Reptiles, Treatments, and Cell-Gene Therapy with Dr. Vick 38:01
1 Amyloidosis Exposed: New Hope with Dr. Vick 40:52
1 A Diagnostic Breakthrough for Alzheimer’s with Dr. Jonathon Hill 30:25
प्लेयर एफएम में आपका स्वागत है!
प्लेयर एफएम वेब को स्कैन कर रहा है उच्च गुणवत्ता वाले पॉडकास्ट आप के आनंद लेंने के लिए अभी। यह सबसे अच्छा पॉडकास्ट एप्प है और यह Android, iPhone और वेब पर काम करता है। उपकरणों में सदस्यता को सिंक करने के लिए साइनअप करें।